Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Immunological Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JUNB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JUNB Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for biochemical binding and dimerization assays. |
View JUNB Products |
| Gene Delivery | JUNB Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and over-expression studies. |
View JUNB Products |
| Benchmark Ab | Anti-JUNB Recombinant Antibody Recombinant positive control for western blot, IHC, and chromatin immunoprecipitation (ChIP) validation. |
View JUNB Products |
| Validator | JUNB siRNA Set For specific knockdown verification in phenotypic and functional assays. |
View JUNB Products |
| Related Target A | FOS Key dimerization partner forming the AP-1 transcription factor complex with JUNB. |
View FOS Products |
| Related Target B | JUND Homologous AP-1 family member; critical for selectivity and off-target safety screening. |
View JUND Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| AP-1 Dimerization Screening | High-purity recombinant JUNB and FOS proteins designed for precise in vitro interaction assays. |
| Intracellular Specificity Validation | Sequence-verified siRNA sets and Lentivirus tools to confirm target-specific phenotypic effects. |
| Lack of Controls | Clinical-grade benchmark antibodies included for assay standardization. |
| False Positives | Validated siRNA knockout panels included for rigorous specificity checks. |
Live JUNB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JUNB therapeutics is intensifying, with major players shifting focus from traditional indirect pathway inhibitors to direct transcriptional modulation and targeted protein degradation (PROTACs). As first-generation AP-1 pathway therapies reach the clinic, the next wave of R&D is targeting JUNB specifically to overcome drug resistance in immunotherapy and targeted oncology regimens.
JUNB acts as a pivotal transcription factor regulating cell proliferation, differentiation, and T-cell exhaustion. In oncology, upregulation of JUNB is strongly associated with resistance to MAPK pathway inhibitors and immune checkpoint blockade. Consequently, developing selective inhibitors, molecular glues, or PROTACs that target the JUNB/AP-1 complex is a high-priority frontier in drug discovery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Degraders | Arvinas, C4 Therapeutics, Academic Labs | Multiple Myeloma, Lymphomas, Solid Tumors | Degradation kinetics assays (Need sequence-verified JUNB proteins and transfection-ready Lentivirus) |
| Small Molecule Inhibitors | Biotech Consortia, Novartis (indirect) | Autoimmune Diseases, Fibrosis, Melanoma | Dimerization disruption assays (Need high-purity JUNB and FOS recombinant proteins) |
| RNAi / ASOs | Alnylam, Ionis Pharmaceuticals | Inflammatory Disorders, Cutaneous T-cell Lymphoma | In vitro knockdown verification (Need validated siRNA sets and qPCR controls) |